Mednet announces new award program for research organizations conducting oncology studies

0

The company will offer 25% discount on iMednet software and service fees to support any type of oncology research

Posted: October 21, 2021 at 11:50 a.m. EDT|Update: 21 minutes ago

MINNEAPOLIS, 21 October 2021 / PRNewswire / – Mednet, a healthcare technology company, has announced a new program to support research organizations conducting all types of oncology-related research. Mednet’s comprehensive clinical data management system (CDMS) is designed to be highly flexible to enable rapid and efficient study constructions and the execution of any type of clinical research. Mednet announced the program in recognition of Breast Cancer Awareness Month (October), Lung Cancer Awareness Month (November), Stomach Cancer Awareness Month (November) and of Pancreatic Cancer Awareness (November). The new program is designed to make it even easier for research organizations to conduct critical oncology research.

MedNet Logo (PRNewsfoto / MedNet)

The design of oncology research, especially registry studies, can be incredibly complex. Variations in treatment regimens such as chemotherapy, radiation therapy, surgery, hormone replacement, etc. may change or be discontinued at any time during the study depending on the patient’s response. Clinical research technology solutions must be able to adapt to highly complex designs, while providing great flexibility to accommodate evolving testing requirements. The iMednet platform is designed to allow research teams to easily conduct oncology trials with flexible and dynamic technology.

The new rebate program will offer research organizations with qualifying projects a twenty-five percent (25%) discount off the list price of iMednet software license fees for the duration of their clinical study. The discount applies to all components of Mednet’s CDMS, including premium modules such as randomization, trial supply management, adjudication, payments and more. Mednet service charges are included, but the discount does not apply to third-party software integrations. Studies contracted on or before January 31, 2022 Is eligible.

“Over the years, significant advances have been made in the treatment of cancer, a direct result of important work carried out by research organizations around the world. Yet, as we all know, there is still work to be done, ”said Rick bernstein, Commercial Director, Mednet. “Research and life science organizations hold the keys to identifying new treatments and finding cures. As an eClinical company dedicated to helping researchers develop life-saving treatments, we want to make it easier for these organizations to access the tools they need to set up their critical studies. and run as fast as possible. “

The Mednet team has supported hundreds of oncology research trials around the world. These trials range from small early stage studies to large global registry trials. To find out more about the Mednet experience or how to access this new reduction program, Contact us.

About Mednet
Mednet is a healthcare technology company specializing in eClinical solutions designed for the global life science community. Mednet’s clinical data management system improves the efficiency of clinical studies of all types and sizes. Beyond Electronic Data Capture (EDC), Mednet’s comprehensive solution set provides the tools to create and manage all types of clinical research, while enabling organizations to adapt to changing demands. demands and requirements. Pharmaceuticals, medical devices, biotechnology and contract research (CRO) organizations around the world have trusted Mednet for nearly 20 years to provide the technological innovation, experience and reliability they need to be successful. For more information visit www.mednetsolutions.com.

Contact: Barbara correll, [email protected]

View original content to download multimedia:

SOURCE Mednet

The above press release has been provided courtesy of PRNewswire. The views, opinions and statements contained in the press release are not endorsed by Gray Media Group and do not necessarily state or reflect those of Gray Media Group, Inc.


Source link

Share.

About Author

Comments are closed.